The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Updated PALOMA-2 results: subcutaneous amivantamab + lazertinib in NSCLC
Misako Nagasaka, MD, PhD, University of California, Irvine, CA, explores results from the PALOMA-2 (NCT05498428) trial, providing an insight into the efficacy of subcutaneous amivantamab in a treatment-naïve population with non-small cell lung cancer (NSCLC). Pooled analysis shows an overall response rate of 90%, a complete response rate of 9% and median progression-free survival of 26.1 months. Overall survival data is not yet mature, but at the three-year mark, the overall survival rate of 70% is favorable compared with findings from the MARIPOSA (NCT04487080) trial. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
